{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
PTC Therapeutics, Inc.
PTC Therapeutics Hits New 52-Week High of $69.26, Up 82.16%
PTC Therapeutics, Inc. achieved a new 52-week high of USD 69.26 on October 15, 2025, following a significant increase from its 52-week low of USD 35.51. The company, with a market cap of USD 4,524 million, has shown strong performance in the Pharmaceuticals & Biotechnology sector.
PTC Therapeutics, Inc. Hits New 52-Week High of $67.40
PTC Therapeutics, Inc. achieved a new 52-week high on October 3, 2025, reflecting strong performance in the pharmaceuticals and biotechnology sector. The company has seen a significant increase over the past year, with a market capitalization of USD 4,524 million and a low return on equity.
Is PTC Therapeutics, Inc. technically bullish or bearish?
As of September 2, 2025, PTC Therapeutics, Inc. shows a bullish trend supported by strong indicators like MACD and Bollinger Bands, despite a bearish weekly RSI, and has significantly outperformed the S&P 500 with a 1-month return of 26.27% and a 1-year return of 77.23%.
PTC Therapeutics Hits New 52-Week High of $63.19, Up 67% Yearly
PTC Therapeutics, Inc. has achieved a new 52-week high, reflecting a substantial increase from its previous low. The company, with a market capitalization of USD 4,524 million, operates in the Pharmaceuticals & Biotechnology sector. Despite challenges in profitability and a high debt-to-equity ratio, its stock performance has notably outpaced the S&P 500.
Is PTC Therapeutics, Inc. technically bullish or bearish?
As of June 9, 2025, PTC Therapeutics, Inc. shows a mildly bullish trend, supported by daily moving averages, but mixed signals from weekly indicators and Bollinger Bands suggest a cautious outlook.
Who are in the management team of PTC Therapeutics, Inc.?
As of March 2022, the management team of PTC Therapeutics, Inc. includes CEO Dr. Stuart Peltz and Independent Chairman Mr. Michael Schmertzler, along with several independent directors: Dr. Allan Jacobson, Ms. Stephanie Okey, Ms. Emma Reeve, Mr. David Southwell, and Dr. Glenn Steele. This team provides governance and strategic direction for the company.
What does PTC Therapeutics, Inc. do?
PTC Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines for rare disorders, with recent net sales of $1.176 billion and a market cap of $4.03 billion. The company has a P/E ratio of 6.00 and no dividend yield.
How big is PTC Therapeutics, Inc.?
As of Jun 18, PTC Therapeutics, Inc. has a market capitalization of $4.03 billion, with net sales of $1.77 billion and a net profit of $594.84 million over the latest four quarters. The company reported shareholder's funds of -$1.10 billion and total assets of $1.72 billion as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
